Carl Sloan, MD
Ophthalmology · Myrtle Beach, SCNPI 1235350117
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,850 of the $78,106 with a category attached, or 79.2%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 61.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $24,951 and has fallen 51.9% since, to $11,991 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $257.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$48K
- Bausch & Lomb Americas Inc.$24K
- AbbVie$2K
- Alcon$2K
- Kala Pharmaceuticals, Inc.$288
- Johnson & Johnson Surgical Vision, Inc.$258
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$61,85079%
- Travel & lodging$8,35211%
- Food & beverage$7,90410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 52 | $48,306 |
| Bausch & Lomb Americas Inc. | 44 | $24,231 |
| AbbVie(2 entities) | 80 | $2,224 |
| Alcon | 67 | $1,684 |
| Kala Pharmaceuticals, Inc. | 5 | $288 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $258 |
| Sun Pharmaceutical Industries Inc. | 7 | $211 |
| Novartis | 12 | $207 |
| Sight Sciences, Inc. | 2 | $95 |
| Glaukos Corporation | 2 | $91 |
| Ivantis, Inc | 4 | $84 |
| Biotissue Holdings Inc. | 3 | $84 |
| Thea Pharma Inc. | 3 | $76 |
| Rayner Intraocular Lenses Limited | 3 | $63 |
| Shire North American Group Inc | 2 | $36 |
| Oyster Point Pharma, Inc. | 2 | $33 |
| Aerie Pharmaceuticals, Inc. | 2 | $28 |
| NEW World Medical,inc. | 4 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Rxsight Inc | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$70,892
- XEN GLAUCOMA TREATMENT SYSTEM$380
- Unity$132
- Tecnis Simplicity$131
- XIPERE$127
- Clareon$127
- Centurion$124
- INVELTYS$119
- EYSUVIS$113
How this compares
$78,106 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 649 | $353,636 |
| VyzultaLatanoprostene Bunod | 260 | $166,811 |
| RestasisCyclosporine | 57 | $97,659 |
| CombiganBrimonidine Tartrate/Timolol | 199 | $86,518 |
| XiidraLifitegrast | 42 | $58,410 |
| Alphagan PBrimonidine Tartrate | 133 | $54,049 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 210 | $40,988 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $38,642 |
| Prednisolone Acetate | 746 | $35,654 |
| RhopressaNetarsudil Mesylate | 50 | $34,548 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 92 | $27,686 |
| Brimonidine Tartrate | 465 | $25,613 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,065 | $21,119 |
| Travoprost | 77 | $19,665 |
| Latanoprost | 1,363 | $17,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,224 | $591,8631,038 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $24,231 | $225,221302 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $28 | $73,190111 claims |
| AlconSimbrinza, Azopt | $1,684 | $35,056105 claims |
| NovartisIlevro, Travatan Z | $207 | $12,16235 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa | $48,306 | $11,65645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Myrtle Beach
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- David VromanLadson$61K
- Drew DicksonCharleston$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.